FN1 and cancer: Kenny et al. has demonstrated that the interaction of integrin α5β1-fibronectin between cancer cells and mesothelial cells can be blocked by a monoclonal antibody, resulting in lesser peritoneal metastasis (Kenny et al., 2014).